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Figure 1. Exon 2 skipping in the human ferrochelatase cDNA. (A) Three per cent agarose gel electrophoresis of reverse transcriptase polymerase chain
reaction-amplified ferrochelatase mRNA. The proband (II2), his mother (I2), and his daughter (III1) exhibit a normal polymerase chain reaction product (1.1 kb)
and a short product, indicating the loss of µ100 bp of cDNA. (B) Ferrochelatase cDNA sequence showing the loss of exon 2 in the patient.
Figure 2. Identification of the mutation among the members of the
family. (A) Pedigree. Proband with clinical symptoms is indicated by black
shading. (B) Direct sequencing of intron 1/exon 2 boundary of ferrochelatase
gene showing the G→C tranversion at IVS1–1 in the proband II2, his daughter
III1, and his mother I2.
genomic DNA were therefore sequenced to determine whether or
not a splice mutation was responsible for the loss of exon 2. The results
showed that the mutation is indeed a G→C transversion at the acceptor
site, IVS1–1, and has not been previously reported. The same mutation,
but showing incomplete penetrance, was found in his mother and
daughter (Fig 2, I2, III1).
An IVS1–23 C→T mutation was also found in the proband, his
relatives (I1, II1, and III1) without the IVS1–1 G→C mutation, and
two other unrelated erythropoietic protoporphyria patients (data not
shown). This mutation was reported previously as a possible cause of
Is Human Papillomavirus Type 5 the Putative Autoantigen
Involved in Psoriasis?
To the Editor:
While it iswell recognized that psoriasis is aTcell-mediated inflammatory
disease that results in epidermal proliferation (Griffiths and Voorhees,
1996), the identity of the antigen(s) responsible for T cell activation is
still a matter of debate, as recently discussed by Nickoloff and Wrone-
Smith (1998). A strong correlation has been found between acute guttate
psoriasis and streptococcal infections (Baker et al, 1993), and it has been
proposed that some bacterial surperantigens or antigens might activate T
cells (Telfer et al, 1992; Baker et al, 1993; Valdimarsson et al, 1995;
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exon 2 skipping (Nakahashi et al, 1992), but later refuted (Wang et al,
1994) when it was found in all erythropoietic protoporphyria patients
and in some controls, suggesting that it may play some role in the
pathogenesis of erythropoietic protoporphyria.
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Boehncke, 1996; Norris et al, 1997). It was also hypothesized that super-
antigen-activated T cells might induce abnormal expression of keratin
variants that show close homology with streptococcal M protein, and
might stimulate M protein-specific autoreactive T cells (Valdimarsson et
al, 1995). It should be stressed, however, that although T cells specific
for M protein have been detected in patients with psoriasis, they have as
yet not been shown to cross-react with any skin components.
Based on the model of human skin grafted onto SCID mice, it was
recently postulated that there are two steps in the autoimmune pathways
to psoriasis (Nickoloff and Wrone-Smith, 1998). The first step is consid-
ered to be a polyclonal activation of Vβ restricted CD41 T cell subsets
by some bacterial superantigens (Boehncke et al, 1996; Wrone-Smith
and Nickoloff, 1996). These activated T cells, injected intradermally
into the grafted uninvolved psoriatic skin, induced histologic changes
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resembling psoriasis. It was hypothesized that the second step involves
an autoreactive subset of superantigen-preactivated T cells, which recog-
nize a putative autoantigen in the epidermis (Nickoloff and Wrone-
Smith, 1998). This assumption found confirmation in the studies by
Gilhar et al (1997), who showed that psoriatic lesional T cells, but not
peripheral blood lymphocytes, were responsible for the maintenance of
psoriatic phenotype in the grafted skin. This is also supported by the
findings of prolonged expression of CD69 molecules on autologous
and superantigen-preactivated T cells administered intradermally into
uninvolved psoriatic graft, which presumably are subsequently activated
by putative autoantigen (Nickoloff and Wrone-Smith, 1998); however,
the autoantigen has not been identified.
Our recent study (Favre et al, 1998) strongly suggests that this putative
autoantigen could be the L1 capsid protein of HPV5, a virus specific of
the rare genetic skin disease epidermodysplasia verruciformis (EV) (Orth,
1987; Majewski and Jablonska, 1995). With the use of a very sensitive
nested polymerase chain reaction approach, we demonstrated the pres-
ence of HPV5 DNA in scrapings of lesional skin in about 90% of a large
series of patients with psoriasis. Most patients were found infected with
at least another HPV5-related EV HPV genotype. In contrast, no HPV5
DNA was detected in atopic dermatitis, another T cell-mediated com-
mon inflammatory cutaneous disorder. Importantly, with the use of an
enzyme-linked immunosorbent assay and HPV5 L1 protein assembled
into virus-like particles bearing conformational epitopes, we detected
HPV5-specific antibodies in about 25% of 155 patients with psoriasis
versus only 2%–5% of control individuals, including patients with atopic
dermatitis, allograft recipients, and patients with genital warts (Favre et
al, 1998). Moreover, antibodies to the minor L2 capsid protein of HPV5
were found in an additional 5% of psoriatic patients (Favre, Ait-Ouarabi,
and Orth, unpublished data). The almost constant presence of HPV5 and
other EV HPV in psoriatic lesions, and the detection of antibodies to
conformational epitopes ofHPV5capsid in a proportionof patients, point
to a possible role of EV HPV in the immunopathogenesis of psoriasis.
Indeed, papillomavirus infection of keratinocytes is favored by epi-
dermal proliferation and, in turn, established infection leads to prolifera-
tion of basal keratinocytes. Multiplication of these nonlytic viruses is
restricted to terminally differentiating keratinocytes and viral capsid pro-
teins are detected only in superficial layers of infected epidermis (Orth,
1987). It might thus be hypothesized that nonspecific stimuli, e.g.,
mechanical injury (Koebner phenomenon) or superantigen-activated
T cells, trigger epidermal proliferation that may promote EV HPV5
infection. Because the intraepidermal CD81 T cells were found to show
oligoclonal Vβ expression consistent with classical antigen activation
(Chang et al, 1997), it could be speculated that this virus is the putative
autoantigen.
Psoriasis has an evident genetic component (Schmitt-Egenolf et al,
1996; Trembath et al, 1997) and this background may overcome the
strong host restriction observed in the general population towards HPV5
infection (Orth, 1987). The association of psoriasis with a particular
MHC haplotype (Schmitt-Egenolf et al, 1996) would possibly allow
immune reaction against HPV5 capsid epitopes. It is conceivable that
HPV5 antibodies recognize viral capsid epitopes in the stratum corneum,
which is a main target of immune reaction in psoriasis (Beutner et al,
1987). This might result in complement activation and chemoattraction
of polymorphonuclear leukocytes (PMN) into the stratum corneum
(Munro abscesses), which is a unique feature of psoriasis. Other chemoat-
tractive stimuli, such as IL-8 and various products of arachidonic acid
metabolism released by PMN, may contribute to leukocyte recruitment;
however, they also mediate other inflammatory diseases, in which Munro
abscesses are absent.
The pathogenic significance of HPV5 and also possibly other related
EV HPV in psoriasis requires further study; however, the high prevalence
of HPV5 in psoriatic scales and the detection of specific antibodies in a
significant proportion of patients strongly suggest that this cell-associated
virus might be involved in the autoimmune pathomechanism of psoriasis.
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